Advertisement

Bipolar Disorder

  • Michael Thomson
  • Verinder SharmaEmail author
Chapter

Abstract

Bipolar disorder is a prevalent condition among women of reproductive age. It has been associated with high morbidity, worsened obstetrical outcomes and a significant risk of suicide. The management of this disorder during pregnancy and in the postpartum period involves balancing the risks associated with medication exposure versus the risks associated with untreated or undertreated maternal illness. Existing studies have shown increased risk of mood episode relapses during pregnancy when mood stabilizing medications are discontinued. Other studies have shown even higher risks for relapse during the postpartum period, especially in women who do not take prophylactic medications. Data on the risks associated with mood stabilizing medications have largely been obtained from population-based cohort studies which are prone to confounding factors, and there has been a lack of consistency in the finding of risks between studies. In this chapter we have summarized the available literature on treatment outcomes using pharmacotherapy for bipolar disorder during pregnancy and the postpartum period. We will also discuss studies of relapse rates during pregnancy and postpartum both with and without the use of prophylactic medications.

Keywords

Postpartum Peripartum Perinatal Depression Bipolar Psychosis Mania Psychotropic Psychopharmacology 

References

  1. 1.
    Boden R, Lundgren M, Brandt L, Reutfors J, Andersen M, Kieler H. Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: population based cohort study. BMJ. 2012;345:e7085.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, Kessler RC. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007;64:543–52.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Pedersen CB, Mors O, Bertelsen A, Waltoft BL, Agerbo E, McGrath JJ, Mortensen PB, Eaton WW. A comprehensive nationwide study of the incidence rate and lifetime risk for treated mental disorders. JAMA Psychiat. 2014;71:573–81.Google Scholar
  4. 4.
    Merrill L, Mittal L, Nicoloro J, Caiozzo C, Maciejewski PK, Miller LJ. Screening for bipolar disorder during pregnancy. Arch Womens Ment Health. 2015;18:579–83.PubMedGoogle Scholar
  5. 5.
    Pedersen CA, Johnson JL, Silva S, Bunevicius R, Meltzer-Brody S, Hamer RM, Leserman J. Antenatal thyroid correlates of postpartum depression. Psychoneuroendocrinology. 2007;32:235–45.PubMedGoogle Scholar
  6. 6.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. Washington, DC: American Psychiatric Press; 2013.Google Scholar
  7. 7.
    Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry. 2003;64:161–74.PubMedGoogle Scholar
  8. 8.
    American College of Obstetricians and Gynecologists. Committee Opinion no. 630. Screening for perinatal depression. Obstet Gynecol. 2015;125:1268–71.Google Scholar
  9. 9.
    O'Connor E, Rossom RC, Henninger M, Groom HC, Burda BU, Henderson JT, Bigler KD, Whitlock EP. U.S. Preventive Services Task Force evidence syntheses, formerly systematic evidence reviews. Screening for depression in adults: an updated systematic evidence review for the US Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality; 2016.Google Scholar
  10. 10.
    Sharma V, Xie B. Screening for postpartum bipolar disorder: validation of the Mood Disorder Questionnaire. J Affect Disord. 2011;131:408–11.PubMedGoogle Scholar
  11. 11.
    Thomson M, Sharma V. Weighing the risks: the management of bipolar disorder during pregnancy. Curr Psychiatry Rep. 2018;20:20.PubMedGoogle Scholar
  12. 12.
    Barnett JH, Smoller JW. The genetics of bipolar disorder. Neuroscience. 2009;164:331–43.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Azorin JM, Angst J, Gamma A, Bowden CL, Perugi G, Vieta E, Young A. Identifying features of bipolarity in patients with first-episode postpartum depression: findings from the international BRIDGE study. J Affect Disord. 2012;136:710–5.PubMedGoogle Scholar
  14. 14.
    Inglis AJ, Hippman CL, Carrion PB, Honer WG, Austin JC. Mania and depression in the perinatal period among women with a history of major depressive disorders. Arch Womens Ment Health. 2014;17:137–43.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Munk-Olsen T, Laursen TM, Pedersen CB, Mors O, Mortensen PB. New parents and mental disorders: a population-based register study. JAMA. 2006;296:2582–9.PubMedGoogle Scholar
  16. 16.
    Sharma V, Xie B, Campbell MK, Penava D, Hampson E, Mazmanian D, Pope CJ. A prospective study of diagnostic conversion of major depressive disorder to bipolar disorder in pregnancy and postpartum. Bipolar Disord. 2014;16:16–21.PubMedGoogle Scholar
  17. 17.
    Hernandez-Diaz S, Smith CR, Shen A, Mittendorf R, Hauser WA, Yerby M, Holmes LB. Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012;78:1692–9.PubMedGoogle Scholar
  18. 18.
    Holmes LB, Mittendorf R, Shen A, Smith CR, Hernandez-Diaz S. Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Arch Neurol. 2011;68:1275–81.PubMedGoogle Scholar
  19. 19.
    Sadowski A, Todorow M, Yazdani Brojeni P, Koren G, Nulman I. Pregnancy outcomes following maternal exposure to second-generation antipsychotics given with other psychotropic drugs: a cohort study. BMJ Open. 2013;3:e003062.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Coughlin CG, Blackwell KA, Bartley C, Hay M, Yonkers KA, Bloch MH. Obstetric and neonatal outcomes after antipsychotic medication exposure in pregnancy. Obstet Gynecol. 2015;125:1224–35.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Gentile S, Luigia Fusco M. Placental and fetal effects of antenatal exposure to antidepressants or untreated maternal depression. J Matern Fetal Neonatal Med. 2016;30:1189–99.PubMedGoogle Scholar
  22. 22.
    Nulman I, Koren G, Rovet J, Barrera M, Pulver A, Streiner D, Feldman B. Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression. Am J Psychiatry. 2012;169:1165–74.PubMedGoogle Scholar
  23. 23.
    Wesseloo R, Kamperman AM, Munk-Olsen T, Pop VJ, Kushner SA, Bergink V. Risk of postpartum relapse in bipolar disorder and postpartum psychosis: a systematic review and meta-analysis. Am J Psychiatry. 2015;173:117–27.PubMedGoogle Scholar
  24. 24.
    Viguera AC, Whitfield T, Baldessarini RJ, Newport DJ, Stowe Z, Reminick A, Zurick A, Cohen LS. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry. 2007;164:1817–24.Google Scholar
  25. 25.
    Marengo E, Martino DJ, Igoa A, Scápola M, Fassi G, Baamonde MU, Strejilevich SA. Unplanned pregnancies and reproductive health among women with bipolar disorder. J Affect Disord. 2015;178:201–5.PubMedGoogle Scholar
  26. 26.
    Doyle K, Heron J, Berrisford G, Whitmore J, Jones L, Wainscott G, Oyebode F. The management of bipolar disorder in the perinatal period and risk factors for postpartum relapse. Eur Psychiatry. 2012;27:563–9.PubMedGoogle Scholar
  27. 27.
    Sharma V. Considerations in the pharmacotherapy of bipolar disorder during and after pregnancy. Curr Drug Saf. 2011;6:318–23.PubMedGoogle Scholar
  28. 28.
    Driscoll KE, Sit DKY, Moses-Kolko EL, Pinheiro E, Yang A, Ciolino JD, Eng HF, Luther JF, Clark CT, Wisniewski SR, Wisner KL. Mood symptoms in pregnant and postpartum women with bipolar disorder: a naturalistic study. Bipolar Disord. 2017;19:295–304.PubMedGoogle Scholar
  29. 29.
    Yatham L, Kennedy S, Parikh V, Schaffer A, Bond D, Frey B, Sharma V, Goldetin BI, Rej S, Beaulieu S, Alda M, MacQueen G, Miley RV, Ravindran A, O’Donovan C, McIntosh D, Lam RW, Vazquez G, Kapczinski F, McIntyre RS, Kozicky J, Kanba S, Lafer B, Suppes T, Calabrese JR, Vieta E, Malhi G, Post RM, Berk M. Canadian Network for Mood and Anxiety Treatments (CANMAT)/International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20:97–170.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Leong C, Raymond C, Chateau D, Dahl M, Alessi-Severini S, Falk J, Bugden S, Katz A. Psychotropic drug use before, during, and after pregnancy: apopulation-based study in a Canadian cohort (2001–2013). Can J Psychiatr. 2017;62:543–50.Google Scholar
  31. 31.
    Ghaemi SN, Boiman EE, Goodwin FK. Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study. J Clin Psychiatry. 2000;61:804–8.PubMedGoogle Scholar
  32. 32.
    Schneck CD, Miklowitz DJ, Miyahara S, Araga M, Wisniewski S, Gyulai L, Allen MH, Thase ME, Sachs GS. The prospective course of rapid-cycling bipolar disorder: findings from the STEP-BD. Am J Psychiatry. 2008;165:370–7.PubMedGoogle Scholar
  33. 33.
    Valenti M, Pacchiarotti I, Rosa AR, Bonnin CM, Popovic D, Nivoli AM, Murru A, Grande I, Colom F, Vieta E. Bipolar mixed episodes and antidepressants: a cohort study of bipolar I disorder patients. Bipolar Disord. 2011;13:145–54.PubMedGoogle Scholar
  34. 34.
    Viguera AC, Tondo L, Koukopoulos AE, Reginaldi D, Lepri B, Baldessarini RJ. Episodes of mood disorders in 2,252 pregnancies and postpartum periods. Am J Psychiatry. 2011;168:1179–85.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Ennis ZN, Damkier P. Pregnancy exposure to olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations. A systematic review. Basic Clin Pharmacol Toxicol. 2015;116:315–20.PubMedGoogle Scholar
  36. 36.
    Pariente G, Leibson T, Shulman T, Adams-Webber T, Barzilay E, Nulman I. Pregnancy outcomes following in utero exposure to lamotrigine: a systematic review and meta-analysis. CNS Drugs. 2017;31:439–50.PubMedGoogle Scholar
  37. 37.
    Swartz HA, Frank E, Frankel DR, Novick D, Houck P. Psychotherapy as monotherapy for the treatment of bipolar II depression: a proof of concept study. Bipolar Disord. 2009;11:89–94.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Provencher MD, Hawke LD, Thienot E. Psychotherapies for comorbid anxiety in bipolar spectrum disorders. J Affect Disord. 2011;133:371–80.PubMedGoogle Scholar
  39. 39.
    Lam DH, Watkins ER, Hayward P, Bright J, Wright K, Kerr N, Parr-Davis G, Sham P. A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder: outcome of the first year. Arch Gen Psychiatry. 2003;60:145–52.PubMedGoogle Scholar
  40. 40.
    Scott J, Paykel E, Morriss R, Bentall R, Kinderman P, Johnson T, Abbott R, Hayhurst H. Cognitive-behavioural therapy for severe and recurrent bipolar disorders: randomised controlled trial. Br J Psychiatry. 2006;188:313–20.PubMedGoogle Scholar
  41. 41.
    Dolk H, Jentink J, Loane M, Morris J, de Jong-van den Berg LT. Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations? Neurology. 2008;71:714–22.PubMedGoogle Scholar
  42. 42.
    Newport DJ, Stowe ZN, Viguera AC, Calamaras MR, Juric S, Knight B, Pennell PB, Baldessarini RJ. Lamotrigine in bipolar disorder: efficacy during pregnancy. Bipolar Disord. 2008;10:432–6.PubMedGoogle Scholar
  43. 43.
    Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, Purgato M, Spineli LM, Goodwin GM, Geddes JR. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet. 2011;378:1306–15.PubMedGoogle Scholar
  44. 44.
    Diav-Citrin O, Shechtman S, Ornoy S, Arnon J, Schaefer C, Garbis H, Clementi M, Ornoy A. Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study. J Clin Psychiatry. 2005;66:317–22.PubMedGoogle Scholar
  45. 45.
    Egbe A, Lee S, Ho D, Uppu S. Effect of race on the prevalence of congenital malformations among newborns in the United States. Ethn Dis. 2015;25:226–31.PubMedGoogle Scholar
  46. 46.
    Newport DJ, Calamaras MR, DeVane CL, Donovan J, Beach AJ, Winn S, Knight BT, Gibson BB, Viguera AC, Owens MJ, Nemeroff CB, Stowe ZN. Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. Am J Psychiatry. 2007;164:1214–20.PubMedGoogle Scholar
  47. 47.
    Guberman AH, Besag FM, Brodie MJ, Dooley JM, Duchowny MS, Pellock JM, Richens A, Stern RS, Trevathan E. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia. 1999;40:985–91.PubMedGoogle Scholar
  48. 48.
    Sharma V, Pope CJ. Pregnancy and bipolar disorder: a systematic review. J Clin Psychiatry. 2012;73:1447–55.PubMedGoogle Scholar
  49. 49.
    Grof P, Robbins W, Alda M, Berghoefer A, Vojtechovsky M, Nilsson A, Robertson C. Protective effect of pregnancy in women with lithium-responsive bipolar disorder. J Affect Disord. 2000;61:31–9.PubMedGoogle Scholar
  50. 50.
    Bergink V, Bouvy PF, Vervoort JS, Koorengevel KM, Steegers EA, Kushner SA. Prevention of postpartum psychosis and mania in women at high risk. Am J Psychiatry. 2012;169:609–15.PubMedGoogle Scholar
  51. 51.
    Rosso G, Albert U, Di Salvo G, Scata M, Todros T, Maina G. Lithium prophylaxis during pregnancy and the postpartum period in women with lithium-responsive bipolar I disorder. Arch Womens Ment Health. 2016;19:429–32.PubMedGoogle Scholar
  52. 52.
    National Institute for Health and Care Excellence. Antenatal and postnatal mental health. 2016. https://www.nice.org.uk/guidance/qs115/resources/antenatal-and-postnatal-mental-health-75545299789765.
  53. 53.
    Patorno E, Huybrechts KF, Hernandez-Diaz S. Lithium use in pregnancy and the risk of cardiac malformations. N Engl J. 2017;376:2245–54.Google Scholar
  54. 54.
    Wesseloo R, Wierdsma AI, van Kamp IL, Munk-Olsen T, Hoogendijk WJG, Kushner SA, Begink V. Lithium dosing strategies during pregnancy and the postpartum period. Br J Psychiatry. 2017;211:31–6.PubMedPubMedCentralGoogle Scholar
  55. 55.
    Pennell PB, Newport DJ, Stowe ZN, Helmers SL, Montgomery JQ, Henry TR. The impact of pregnancy and childbirth on the metabolism of lamotrigine. Neurology. 2004;62:292–5.PubMedGoogle Scholar
  56. 56.
    Uguz F. Prophylactic use of olanzapine and quetiapine from pregnancy to the postpartum period in women with bipolar disorder: a case series. J Matern Fet Neonat Med. 2017;30:2569–671.Google Scholar
  57. 57.
    Meakin CJ, Brockington IF, Lynch S, Jones SR. Dopamine supersensitivity and hormonal status in puerperal psychosis. Br J Psychiatry. 1995;166:73–9.PubMedGoogle Scholar
  58. 58.
    Stewart DE, Klompenhouwer JL, Kendell RE, van Hulst AM. Prophylactic lithium in puerperal psychosis. The experience of three centres. Br J Psychiatry. 1991;158:393–7.PubMedGoogle Scholar
  59. 59.
    Sharma V, Smith A, Mazmanian D. Olanzapine in the prevention of postpartum psychosis and mood episodes in bipolar disorder. Bipolar Disord. 2006;8:400–4.PubMedGoogle Scholar
  60. 60.
    Wesseloo R, Liu X, Clark CT, Kushner SA, Munk-Olsen T, Bergink V. Risk of postpartum episodes in women with bipolar disorder after lamotrigine or lithium use during pregnancy: a population-based cohort study. J Affect Disord. 2017;218:394–7.PubMedPubMedCentralGoogle Scholar
  61. 61.
    Sharma V, Khan M, Sommerdyk C. Quetiapine in the acute treatment of bipolar postpartum depression: a chart review. J Clin Psychopharmacol. 2015;35:733–5.PubMedGoogle Scholar
  62. 62.
    Misri S, Abizadeh J, Eng A, Ryan D, Swift E. An open-label study of quetiapine extended-release in a sample of postpartum women with bipolar II depressive episode. Curr Psychopharmacol. 2015;4:16–26.Google Scholar
  63. 63.
    VanderKruik R, Barreix M, Chou D, Allen T, Say L, Cohen LS. The global prevalence of postpartum psychosis: a systematic review. BMC Psychiatry. 2017;17:272.PubMedPubMedCentralGoogle Scholar
  64. 64.
    Kamperman AM, Veldman-Hoek MJ, Wesseloo R, Robertson Blackmore E, Bergink V. Phenotypical characteristics of postpartum psychosis: a clinical cohort study. Bipolar Disord. 2017;19:450–7.PubMedGoogle Scholar
  65. 65.
    Sit D, Rothschild AJ, Wisner KL. A review of postpartum psychosis. J Women’s Health. 2006;15:352–68.Google Scholar
  66. 66.
    Spinelli MG. Maternal infanticide associated with mental illness: prevention and the promise of saved lives. Am J Psychiatry. 2004;161:1548–57.PubMedGoogle Scholar
  67. 67.
    Spinelli MG. Postpartum psychosis: detection of risk and management. Am J Psychiatry. 2009;166:405–8.PubMedGoogle Scholar
  68. 68.
    Bergink V, Burgerhout KM, Koorengevel KM, Kamperman AM, Hoogendijk WJ, Lambregtse-van den Berg MP, Kushner SA. Treatment of psychosis and mania in the postpartum period. Am J Psychiatry. 2015;172:115–23.PubMedGoogle Scholar
  69. 69.
    Lewis KJS, Di Florio A, Forty L, Gordon-Smith K, Perry A, Craddock N, Jones L, Jones I. Mania triggered by sleep loss and risk of postpartum psychosis in women with bipolar disorder. J Affect Disord. 2018;225:624–9.PubMedGoogle Scholar
  70. 70.
    Sharma V, Mazmanian D. Sleep loss and postpartum psychosis. Bipolar Disord. 2003;5:98–105.PubMedGoogle Scholar
  71. 71.
    Sharma V, Sommerdyk C, Xie B, Campbell K. Pharmacotherapy of bipolar II disorder during and after pregnancy. Curr Drug Saf. 2013;8:246–52.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of PsychiatryWestern UniversityLondonCanada
  2. 2.Department of Obstetrics and GynecologyWestern UniversityLondonCanada

Personalised recommendations